ent study, in which 11 patients were given estrogen, had a dual objective: 1) to determine whether therapeutic benefit follows the elevation of ceruloplasmin; and 2) by altering in a normal direction certain parameters characteristic of the genetically abnormal state, to obtain further information concerning the disturbance of copper metabolism in Wilson's disease. During the prolonged period of the study. serum copper and ceruloplasmin levels, urinary copper excretion, and clinical status of the patients were observed.
METHODS
Twenty-four-hour urine specimens were collected in acid-cleaned vessels and were stored at 40 C using thymol crystals as preservative. Urine and serum copper determinations were carried out in duplicate by methods previously described (28, 29) . Serum ceruloplasmin was estimated either by the method of Bearn and Kunkel (29) and Holmberg and Laurell (30) or by a modification of Broman's method (31) , all of which employ paraphenylenediamine as substrate. The serum copper calculated to be incorporated in ceruloplasmin was based on a copper content of this protein of 0.34 per cent (32) ; the copper present in the serum in excess of this was considered to be loosely bound to albumin (11) and is referred to as non-ceruloplasmin copper. Ethinyl estradiol (Estinyl, Schering Corp.), 5.0 mg daily, was administered during 16 courses to 11 patients (Table I) .
Clinical material. The 11 patients with Wilson's disease in this study exhibited varying degrees of neurological and hepatic disorder; Table I (fourth column) indicates clinical severity ranging from 0 (no disease detectable) or 1 (minimally affected) to 4 (severely affected). Four individuals were ambulatory and in a stable phase of the disease (AC, FL, CP, LA) ; the remainder were severely disabled. Two cases had severe liver disease in addition to serious neurological manifestations; these two patients exhibited the highest pretreatment levels of ceruloplasmin (RE, VC). The symptoms in the remaining 9 cases were predominantly neurological.
Prior to the administration of estrogens, clinical and biochemical evaluation of each patient was made. Other forms of therapy 1 which might interfere with the study 1 copper and the degree of cupruresis. A parallel increase between serum copper and ceruloplasmin was frequently observed during the initial phase of the response. Subsequently, the ceruloplasmin level tended to become stable while both the total copper (and, therefore, the non-ceruloplasmin copper) and the urinary copper increased further. There was also a clinical correlation: patients whose condition deteriorated showed, in general, a high non-ceruloplasmin copper level either prior to or in response to estrogen treatment. Patients whose condition either improved or did not change showed a decrease or little change in the nonceruloplasmin copper level. Some patients exhibited cupruresis without a ceruloplasmin rise; however, all of those who showed cupruresis had an increase in total serum copper, which suggests that a rise in non-ceruloplasmin copper is related to an increase in urinary copper excretion.
Clinical results. exhibited initial neurological improvement but subsequent marked deterioration with only minimal improvement following cessation of treatment. Although both of these patients died of Wilson's disease within months following treatment, they were severely affected prior to the study.
One patient (MP) showed mild improvement during her initial course and no change during the second course which was superimposed upon penicillamine administration. VC (Figure 4) showed striking improvement when given estrogen. Prior to treatment she had become markedly debilitated, displaying severe hepatic and neurological symptoms. Prompt and extensive neurological improvement and weight gain from 35 to 47 kg occurred during the first three courses of treatment. She progressed from being bedridden to a condition in which she could be discharged from the hospital for short periods. Toward the end of each course of treatment and in the period following discontinuation of the hormone, neurological deterioration occurred. When her last course was initiated she showed severe neurological disease, and only slight improvement occurred during estrogen administration. Her biochemical response during the first courses was unique, as previously indicated. Although she is the single instance of striking improvement associated with estrogen therapy, this treatment seemed largely responsible for her survival early in the hospital course when death apparently was impending and, further, enabled her to withstand major surgery (course 3).
During estrogen administration three patients developed phlebothrombosis, in one case associated with pulmonary embolism. No consistent coagulation abnormalities could be detected.3 DISCUSSION A notable lack of uniformity was evident in the response to estrogen administration of the 11 patients with Wilson's disease. It is clear (Table  II) that such treatment usually leads to an alteration of copper metabolism. The nonhomogeneity in response is a further example of the clinical and biochemical variation seen in patients with this disorder (6) . This, of course, does not neces- sarily imply genetical nonhomogeneity, but could equally represent the result of varying internal environments or compensatory physiological mechanisms, as well as modifying genes.
In many respects the patient with Wilson's disease in whom total copper and ceruloplasmin concentrations are brought toward normal by administration of estrogen is comparable with the rare patient who, at some phase of his disease, exhibits total levels in the normal range (33, 34) . The reason for the increased concentration of ceruloplasmin in such unusual cases is not immediately apparent. It is noteworthy that two such patients, both males, described by Sass-Kortsak, Cherniak, Geiger and Slater (33) had severe liver disease without neurological symptoms; one showed gynecomastia and delay in maturation of male sexual characteristics. Our (35) (36) (37) . It is known that the concentration of a number of serum components increases during pregnancy or estrogen administration; these include fibrinogen, al-, a2-, and p-globulins (38) (39) (40) (41) (42) , ceruloplasmin (43) , transcortin (44), and the thyroxine-binding a-globulin of serum (45, 46) . Also, the serum copper level may rise during pregnancy (19) (20) (21) (22) (23) 47) or estrogen administration (24, 25, 43, 48 Although the administration of estrogen to patients with Wilson's disease may in some instances result in increase in the serum concentration of copper and ceruloplasmin, it is not usually of therapeutic value. Although only 11 patients have been treated, and although the course of the disease is unpredictable, treatment with estrogens has been associated with increased rate of neurological decline in over half of the patients. Further, some patients in a stable phase of the disease have abruptly shown the onset of deterioration in association with administration of estrogen. Increasing neurological symptoms, increasing cupruresis, and rising non-ceruloplasmin copper concentration are all accentuations of characteristic manifestations of the preexisting disease. In the presence of this specific genetical abnormality, the efforts of the cell to increase ceruloplasmin synthesis in response to estrogen may be partially effective, as observed in 4 of 11 patients, but these efforts are usually simultaneously associated with increase in the disease processes. The lack of improvement seen in some patients whose ceruloplasmin concentrations increase is evidence that the low level of this protein per se is not critical in determining the presence or absence of the clinical and pathological findings of the disease.
Several observations made during the study thus indicate that although a trend toward normalitv in total serum copper and serum ceruloplasmin may be established, other events may take place simultaneously which are seriously deleterious. The increase in the non-ceruloplasmin component of serum copper (49) , though associated with striking cupruresis, is also associated with increase of neurological symptoms. It is unclear whether the increase in this compartment of serum copper itself is the deleterious event or is only an associated occurrence. SUM MARY 1. Ethinyl estradiol was administered to eleven patients with Wilson's disease. In four patients the serum copper and ceruloplasmin concentrations and the urinary copper excretion increased. In six patients there was an increase in the serum copper concentration, three of whom showed cupruresis. The levels of serum copper and ceruloplasmin and the urinary copper excretion showed no change in one patient.
2. One patient improved clinically, four were unchanged, and six deteriorated during the estrogen administration.
3. The interrelationships of total serum copper. non-ceruloplasmin serum copper, ceruloplasmin, urinary copper excretion, and clinical change were investigated. Neither ceruloplasmin elevation nor cupruresis necessarily led to improvement. Cupruresis and clinical deterioration could, in general, be correlated with an increase in the non-ceruloplasmin fraction of serum copper.
